about
The current state of adverse event reporting in hemophilia.The detrimental effects of iron on the joint: a comparison between haemochromatosis and haemophilia.Differential effects of bleeds on the development of arthropathy - basic and applied issues.Pathophysiology of hemophilic arthropathy and potential targets for therapy.First preclinical support for the 'danger theory' in inhibitor development.von Willebrand disease and extra-intestinal angiodysplasia.Biochemical markers of joint tissue damage increase shortly after a joint bleed; an explorative human and canine in vivo study.A fusion protein of interleukin-4 and interleukin-10 protects against blood-induced cartilage damage in vitro and in vivo.IL-1β, in contrast to TNFα, is pivotal in blood-induced cartilage damage and is a potential target for therapy.Joint distraction: a treatment to consider for haemophilic arthropathy.Severe Wound Healing Impairment in a Patient with Dysfibrinogenaemia.Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia ABortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissionsJoint disease in haemophilia: Pathophysiology, pain and imagingThe combination of urinary CTX-II and serum CS-846: Promising biochemical markers to predict radiographic progression of haemophilic arthropathy-An exploratory studyProteoglycan synthesis rate as a novel method to measure blood-induced cartilage degeneration in non-haemophilic and haemophilic ratsAn update on the 'danger theory' in inhibitor development in hemophilia ASynovitis and synovectomy in haemophilia
P50
Q30239952-0F7AC6A5-CC16-4E61-BAC8-C470CB158E57Q38432393-71FD2D48-7801-4E0B-9CE3-B13975CCA7FBQ38692376-9AC72F43-1209-4964-9229-E833E84A84F8Q39021649-8C190E46-FA04-4C74-8E59-A291D9ACEB08Q45856783-B39C5D84-A700-423E-9853-71C793219BF4Q45868451-47FE8C28-1811-41C2-8655-DFFFAD5C721DQ45868569-2928016C-26B8-49DC-84EE-D878A09518FEQ45869681-8B893B6E-954F-4A0A-A31C-E4F060E41346Q45878583-025F89A1-1651-4507-A529-148B8B8532ABQ45881637-4C8CF094-9D8A-4E69-AA3A-87C88360D704Q50240580-9614FE3E-96E0-4207-8A61-1EF4B4D414E6Q59468812-FE965370-9546-47CA-AED4-13129A7CCB31Q83378258-05F56F85-6EE0-4D07-9F01-0DF8F8C1E638Q89024109-62F96C5C-D485-42AF-99D5-09FC895CBDAFQ90462884-7F3AB8F3-CB61-405C-BACD-BF23E181FB60Q90650716-173B4AFD-7422-40A5-92BB-C2EF20739679Q92876495-A89EC0EC-4353-42CD-8A2C-51C85674D41DQ96113446-C4EB95C3-613C-4608-9915-F3497C440B01
P50
description
investigador
@es
researcher
@en
name
L F D van Vulpen
@en
type
label
L F D van Vulpen
@en
prefLabel
L F D van Vulpen
@en
P31
P496
0000-0003-3242-5524